

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner:

Not Yet Assigned

Group Art Unit:

Not Yet Assigned

Applicant:

Keisuke Kuida, et al.

Serial No.:

09/888,182

Filing Date:

June 22, 2001

For:

ERK-5 DEFICIENT ANIMALS AND

METHODS OF INHIBITING ANGIOGENESIS THROUGH THE

INHIBITION OF ERK-5

Cambridge, Massachusetts October 15, 2001

Hon. Assistant Commissioner For Patents Washington, D.C. 20231

RECEIVED

OCT 2 5 2001

OFFICE OF PETITIONS

## PETITION UNDER 37 CFR 1.53(b)

As indicated in the Notice of Incomplete Nonprovisional Application dated August 23, 2001, the filing date has been withheld on the above-identified application due to the application being filed without Figures 1 through 6 which are referred to in the specification. Applicant inadvertantly omitted Figures 34 through 6 in the above-identified application as filed. Because Figures 1 through 6 are not necessary for the understanding of the subject matter sought to be patented, said Figures do not fall under the scope of USC §113 (first sentence). In order to rectify the inadvertant error, applicant has concurrently submitted;

herewith a preliminary amendment to amend the specification to delete all reference to said Figures.

Applicants respectfully request that the filing date of June 22, 2001 be granted for the above-identified application.

Applicants authorize the Commissioner to charge any petition fee due to Deposit Account No 50-0725.

Because the application is entitled to the original filing date of June 22, 2001, applicants request, under 37 CFR 1.26(a), a refund of any petition fee charges to be credited to Deposit Account No. 50-0725.

Respectfully submitted,

Andrea L. C. Robidoux (Reg. No. 47,902)

Agent for Applicants

C/O Vertex Pharmaceuticals Inc.

130 Waverly St.

Cambridge, MA 02139-4242

Tel: (617)444-6731

RECEIVED

OCT 2 5 2001

OFFICE OF PETITIONS